logo
Globavend Regains Compliance with Nasdaq Minimum Bid Price Deficiency

Globavend Regains Compliance with Nasdaq Minimum Bid Price Deficiency

Globavend Holdings Limited (NASDAQ:GVH)
PERTH, AUSTRALIA, May 23, 2025 / EINPresswire.com / -- Globavend Holdings Limited (Nasdaq: GVH) (the 'Company' or 'Globavend'), an emerging e-commerce logistics provider, today announced that it received a notification letter (the 'Notification Letter') from the Listing Qualifications Department of The Nasdaq Stock Market LLC ('Nasdaq') notifying the Company that it has regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2) (the 'Minimum Bid Price Requirement').
The Notification Letter confirmed that the Company evidenced a closing bid price at or greater than the $1.00 per ordinary share minimum requirement for the last 10 consecutive business days, from May 9, 2025 to May 22, 2025, and that the Company has regained compliance with the Minimum Bid Price Requirement. As a result, the listing matter has been closed.
The ordinary shares of the Company continue to trade on Nasdaq under the symbol 'GVH'.
About Globavend Holdings Limited
Globavend Holdings Limited, an emerging e-commerce logistics provider, offers end-to-end logistics solutions in Hong Kong, Australia, and New Zealand. The Company primarily serves enterprise customers, including e-commerce merchants and operators of e-commerce platforms, facilitating business-to-consumer (B2C) transactions. As an e-commerce logistics provider, Globavend delivers integrated cross-border logistics services from Hong Kong to Australia and New Zealand. It provides customers with a comprehensive solution, encompassing pre-carriage parcel drop-off, parcel consolidation, air-freight forwarding, customs clearance, on-carriage parcel transportation, and final delivery.
Wai Yiu Yau
Globavend Holdings Limited
+61 8 6141 3263
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Yahoo

time15 minutes ago

  • Yahoo

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

- Composition of matter patent affirmed, provides protection into 2030 - Builds on recent ruling in favor of Acadia for formulation patent expiring in 2038 SAN DIEGO, June 09, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia's litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc. In its affirmance, the Appeals Court applied the precedent established in Allergan USA, Inc. v. MSN Laboratories Private Ltd., MSN Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, holding that "a first filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a common priority date." "We are gratified that the U.S. Federal Appeals Court has affirmed the lower court's ruling in favor of our composition of matter patent for NUPLAZID, securing protection into 2030 for this patent, and beyond based on the recent favorable ruling for our formulation patent providing patent protection for NUPLAZID 34 mg capsule formulation into 2038," said Catherine Owen Adams, Chief Executive Officer. "These decisions reinforce our commitment to safeguarding the intellectual property that underpins our innovations in addressing serious, unmet medical needs." This follows the U.S. District Court for the District of Delaware ruling in favor of Acadia regarding its '721 formulation patent for NUPLAZID which ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated New Drug Application) filers. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential," "continue" and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) the impact of the court ruling on our business and our ability to defend ourselves in the future; (ii) the continued patent protection for NUPLAZID; and (iii) the anticipated timing for termination of such protections. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our ability to maintain, protect and enhance our intellectual property; the outcome of other existing and potential future lawsuits challenging our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-Q for the quarter ended March 31, 2025 as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law. View source version on Contacts Investor Contacts: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@ Media Contact: Acadia Pharmaceuticals Kazenelson(818) 395-3043media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Mexico's Coppel to Invest $4.2 Billion in E-Commerce, New Stores
Mexico's Coppel to Invest $4.2 Billion in E-Commerce, New Stores

Bloomberg

time26 minutes ago

  • Bloomberg

Mexico's Coppel to Invest $4.2 Billion in E-Commerce, New Stores

By and Valentine Hilaire Save Grupo Coppel SA, Mexico's largest private retailer, will spend 80 billion pesos ($4.2 billion) over five years on investments including a new e-commerce platform to double the portion of digital transactions to 20% of total sales. BanCoppel, its banking branch, will use part of the investment to add 3 million customers from the unbanked population, the company said in a statement. Dozens of brick-and-mortar shops will also be added, Coppel said.

Inflation Cools, Jobs Steady--Is This the Market Rebound Investors Have Been Waiting For?
Inflation Cools, Jobs Steady--Is This the Market Rebound Investors Have Been Waiting For?

Yahoo

time27 minutes ago

  • Yahoo

Inflation Cools, Jobs Steady--Is This the Market Rebound Investors Have Been Waiting For?

Consumer anxiety about rising prices may finally be easingand the timing could matter. According to fresh data from the New York Fed, Americans now see inflation coming in lower than they did just a month ago. Median year-ahead expectations dropped to 3.2% in May, down from 3.6% in April. Three- and five-year views also edged lower, now sitting at 3.0% and 2.6%, respectively. The shift follows a temporary de-escalation in trade tensions, with President Trump agreeing to reduce tariffs on Chinese imports. That announcement, while short-term, may have helped reverse the negative consumer sentiment that had been building since early this year. The job picture isn't boomingbut it might be stabilizing. Americans' perceived risk of losing their job over the next year ticked slightly lower, and more people say they feel confident enough to quit voluntarily. That's typically a positive signal for labor markets. At the same time, the share of households saying they expect to be financially worse off in a year has shrunk, and fewer respondents report difficulty accessing credit. Perhaps more telling: the average probability of missing a loan payment has dropped to its lowest point since Januaryhinting at some relief from financial stress, even as parts of the economy remain under pressure. This shift in sentiment may be influencing how people see the market. More consumers now expect the U.S. stock market to be higher a year from now. That optimism, combined with cooler inflation expectations and fewer job fears, could support short-term risk appetite heading into the summer. The Federal Reserve is widely expected to keep rates on pause at its upcoming June 1718 meeting, giving markets more room to digest the macro shifts. Tesla (NASDAQ:TSLA) and other high-beta names might see increased investor interest if this rebound in consumer confidence translates into steadier flows into equities. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store